Obesity science & practice

Patients' experiences of continuing GLP-1 receptor agonist treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Use of GLP-1 receptor agonists is associated with significant weight loss.

  • Discontinuing GLP-1 receptor agonists may lead to weight regain.
  • The patient experience regarding continuity of care with these medications is not well understood.
  • Understanding patient experiences could inform better management strategies for weight loss.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Aug '26
Use of GLP-1 and GLP-1/GIP Medicines and Their Reported Effects in People with Lipedema from a Large Online Survey
top 20% journal
journal article
Feb '26
Administrative costs of insurance approval for diabetes medications called GLP-1 agonists
top 20% journal
journal article
Oct '25
Healthcare costs and treatment patterns linked to use of diabetes-related medication in patients with fatty liver disease and metabolism problems
top 30% journal
cited by 1 paper
journal article
Jul '26
Stopping glucagon-like peptide-1 receptor drugs among US adults: results from a national survey
top 20% journal
journal article
Mar '26
Community pharmacists' knowledge and counseling skills on diabetes and obesity drugs in Türkiye
top 30% journal
cited by 2 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief